Autopsy report · NCT02531854

A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy

“Study was withdrawn per sponsor decision”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Advaxis, Inc.

Sponsor type

Industry

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

ADXS11-001; Pemetrexed

Participants

0

Trials that died the same way

• Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab
  “Study withdrawn by Sponsor” (94% match in meaning)
• Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial
  “Sponsor withdrew the study” (93% match in meaning)
• NRX-1074 in Early Course Schizophrenia
  “The study was withdrawn by the sponsor.” (90% match in meaning)
• Effects of AffronEye®/ Crocuvis+® on Dry Eye Syndrome
  “Study withdrawn prior to enrollment due to sponsor decision” (90% match in meaning)
• A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a
  “Sponsor decision to withdraw study at this time.” (88% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.